Credits: Canva
Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".
In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.
Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.
Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.
The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.
Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.
Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.
Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.
Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.
However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.
The Union Minister of Health and Family Welfare, JP Nadda, today launched two key national initiatives -- the Strategy for Artificial Intelligence in Healthcare for India (SAHI) and the Benchmarking Open Data Platform for Health AI (BODH) to boost the role of AI in the country's healthcare ecosystem.
The initiatives, launched at the India AI Summit at Bharat Mandapam, in the national capital, are aimed at promoting safe, transparent, and accountable AI in healthcare. It will also help strengthen the digital health ecosystem for equitable healthcare access.
SAHI is a national guidance framework to enable the safe, ethical, evidence-based, and inclusive adoption of AI across India’s healthcare system.
It aims to provide strategic direction on governance, data stewardship, validation, deployment, and monitoring of AI solutions, while supporting States and institutions in responsible adoption aligned with public health priorities.
"SAHI is not merely a technology strategy but a governance framework, policy compass, and national roadmap for the responsible use of AI in healthcare,” said Nadda.
He stated that SAHI will guide India in leveraging AI in a manner that is ethical, transparent, accountable, and people-centric. Nadda also emphasized that SAHI provides a structured framework for collaboration, ensuring that innovation flourishes while public interest remains paramount.
The second initiative, BODH, was developed by the Indian Institute of Technology Kanpur in collaboration with the National Health Authority. It is a privacy-preserving benchmarking platform that enables rigorous evaluation of AI models using diverse, real-world health data without sharing underlying datasets.
As a digital public good under the Ayushman Bharat Digital Mission, it is designed to strengthen trust, transparency, and quality assurance in Health AI deployment.
"The collaboration between Government and academia has led to the development of BODH -- the Benchmarking Open Data Platform for Health AI -- which provides a structured mechanism for testing and validating AI solutions before deployment at scale,” said Nadda.
Nadda reiterated that AI solutions must be rigorously evaluated for performance, reliability, and real-world readiness. Together, SAHI and BODH represent India’s commitment to building a trustworthy, inclusive, and globally competitive health AI ecosystem grounded in innovation, responsibility, and public trust.
Earlier, delivering the keynote address at a session themed “Innovation to Impact: AI as a Public Health Game-Changer”, at the Summit, Anupriya Patel, Union Minister of State for Health and Family Welfare, highlighted AI as an "All-Inclusive Intelligence".
She also emphasized AI's potential in addressing "health inequities across the country".
Patel called technology -- particularly AI "an indispensable enabler" in India's race towards the vision of a Viksit Bharat by 2047.
She highlighted the potential role of AI on India’s vast and diverse population, the rural–urban divide, and the dual burden of communicable and non-communicable diseases, which present unique challenges.
She also noted that AI has been integrated across the entire continuum of healthcare -- from disease surveillance and prevention to diagnosis and treatment.
Credit: Canva
While the national capital is seeing a significant rise in H3N2 Influenza A cases, experts explained that it's not just the common cold and people must not try to self-medicate.
Speaking to Health And Me, multiple experts stressed the need to treat the virus properly, as its symptoms can last longer and potentially lead to pneumonia.
H3N2 is a subtype of the Influenza A virus that causes seasonal flu. The symptoms are often stronger and more persistent, with many patients reporting prolonged fatigue, cough, breathing difficulty, and slower recovery.
It is highly contagious, spreading via respiratory droplets (coughing/sneezing) and contaminated surfaces. The symptoms usually last 5–7 days, with treatment focusing on rest and symptom management.
Dr. Mohit Saran, Consultant - Internal Medicine and Diabetologist, Manipal Hospital, Gurugram, told this publication: “H3N2 is not just a common cold. While symptoms may not appear instantly, they can lead to high fever, constant cough, body pain, and breathing issues. In some people, this can also increase the risk of pneumonia or the need for hospitalization if not managed early.”
The experts attributed the surge in the disease to factors such as changing weather, fluctuating temperatures and reduced immunity.
Children, youngsters, senior citizens, pregnant women and people with low immunity or with conditions such as asthma, diabetes, or heart problems are more vulnerable to H3N2. Health care professionals and people who are exposed to crowded places may also be affected by this disease.
Dr. Atul Gogia, Head of Infectious Diseases, Sir Ganga Ram Hospital, told Health and Me that the H3N2 virus "predominantly affects elderly people and those who have comorbid illnesses".
"We need to be especially careful because this illness predominantly affects individuals with comorbid conditions, the elderly, and those who are more vulnerable to developing complications that may require hospitalization,” he said.
Symptoms of H3N2 infection can last for two to three weeks, with a lingering dry cough and fatigue being common.
The virus often affects the lower respiratory tract, leading to more intense coughing and breathing discomfort. Young children, older adults, and individuals with chronic health conditions are at higher risk of complications.
"H3N2 is considered more infectious because of its ability to mutate quickly and adapt to the human host. This high mutation rate allows the virus to evade the immune system more effectively and can lead to more severe outbreaks. It spreads easily through respiratory droplets, direct contact, and contaminated surfaces,” explained Dr. Manisha Arora, Director - Internal Medicine at the CK Birla Hospital(R), Delhi told HealthandMe
"Frequent changes in its surface proteins, a process known as antigenic drift, make it harder for the body to recognize and fight the virus, which can result in more hospitalizations and, in severe cases, increased mortality,”
H3N2 can be prevented through regular handwashing, wearing masks in crowded places, avoiding close contact with people who are sick, and avoiding self-medicating. Flu vaccination, timely medical consultation for long-term fever, and adequate rest help reduce the risk and further spread of the condition.
The experts recommended that all adults above 18 consider annual flu vaccination ideally in August or September, unless they are currently experiencing flu-like symptoms.
Maintaining good hygiene, eating nutrient-rich foods, staying hydrated, and following healthy habits can help boost immunity.
Credit: TOI
Over 70 residents in Supertech Ecovillage-3, Royal Court Society and Himalaya Pride Society, Greater Noida have contracted food poisoning after they consumed a specific batch of buckwheat (kuttu) flour during Mahashivratri this weekend.
The widespread outbreak has caused panic and triggered a police investigation. As a result, officials sealed Prashant General Store, a retail shop in Royal Court Society and HD Spices, a primary warehouse in Chipiyana Buzurg village suspected of selling the spoiled batch.
Moreover, four people including the warehouse owner have now been detained by the Bisrakh police. Assistant Commissioner of Food, Noida, Sarvesh Kumar said lab tests are yet to confirm whether the infection was due to bacterial contamination, fungal toxins or adulteration.
This incident adds to a troubling trend of food and water contamination in the area, a topic that has recently reached discussions in Parliament. Improper storage allows toxic molds like aflatoxins to grow, triggering rapid-onset vomiting and dehydration, especially on the empty stomachs of fasters.
This "Buckwheat flour poisoning" occurs because the flour's high natural oil content makes it highly perishable; when stored in humid or warm conditions, these oils oxidize, creating a breeding ground for toxic molds and bacteria.
Despite its reputation as a "pure" fasting food, buckwheat flour carries a hidden risk: its high natural oil content. Unlike refined grains, these healthy fats are highly unstable; when exposed to heat or moisture, they oxidize and turn rancid.
This transformation from a nutrient-dense staple to a source of food poisoning commonly occurs when households treat it like a non-perishable grocery item rather than the sensitive, short-lived ingredient it actually is.
The real danger of buckwheat flour lies in storage. Because buckwheat flour is used sporadically, it often sits in pantries in unsealed packets, warm cupboards or humid environments for months and becomes a silent breeding ground for dangerous molds and bacteria over time
The degradation is often hard to spot; a faint bitter aroma or slightly clumpy texture can easily be hidden by the strong spices and oils used in traditional fasting recipes.
Along with this, expired or damp buckwheat flour can harbor aflatoxins and other toxic compounds beneath the surface. Once ingested, these irritants attack the stomach lining, triggering a rapid physical "rejection," usually within just a few hours.
While anyone can get food poisoning, women, children and the elderly are at the highest risk. The practice of fasting can actually make the illness more dangerous. On an empty stomach, even a small amount of mold or bacteria can trigger an explosive physical response.
Furthermore, fasting usually involves lower water intake; once vomiting or diarrhea begins, the body loses its remaining fluid reserves instantly, leading to rapid, severe dehydration.
© 2024 Bennett, Coleman & Company Limited